Omnicell (OMCL)
NASDAQ:OMCL
Want to see OMCL full AI Analyst Report?
OMCL Stock Chart & Stats
$38.28
-$0.19(-0.44%)
At close: 4:00 PM EST
$38.28
-$0.19(-0.44%)
Day’s Range― - ―
52-Week Range$26.85 - $55.00
Previous CloseN/A
Volume97.52K
Average Volume (3M)549.49K
Market Cap
$1.72B
Enterprise Value$1.92B
Total Cash (Recent Filing)$290.96M
Total Debt (Recent Filing)$202.18M
Price to Earnings (P/E)83.9
Beta0.53
Next Earnings
Jul 30, 2026EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding45,478,910
10 Day Avg. Volume650,606
30 Day Avg. Volume549,485
Financial Highlights & Ratios
PEG Ratio-12.16
Price to Book (P/B)1.69
Price to Sales (P/S)1.76
P/FCF Ratio23.97
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit3.60
Enterprise Value/Ebitda15.39
Forecast
1Y Price Target
$65.00Price Target Upside69.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.78
Revenue Forecast (FY)$1.25B
Bulls Say, Bears Say
Bulls Say
Balance Sheet DeleveragingMaterial deleveraging meaningfully lowers financial risk and interest burden, giving durable flexibility to fund product rollouts, strategic investments, or buybacks. A cleaner capital structure supports multi-quarter stability and optionality even if earnings recover slowly.
Strong Cash GenerationSustained operating and free cash flow provide a reliable funding source for R&D, SaaS deployments, and service expansion without depending solely on volatile net income. Strong FCF supports debt reduction, working capital and multi-year software rollouts.
Product & Recurring Revenue MomentumNew hardware (Titan XT) and platform (OmniSphere) create a multi-year replacement cycle plus a scalable SaaS path, supporting structural ARR growth and higher recurring revenue mix. Backlog and ARR targets indicate durable commercial traction and cross-sell potential.
Bears Say
Weak Underlying ProfitabilityVery thin net margins and low returns constrain the company's ability to self-fund expansion and absorb shocks. Without sustained margin improvement or a shift to higher-margin recurring revenue, shareholder profitability and reinvestment capacity remain limited.
Long Capital Approval CyclesStructural long sales and capital approval timelines in health systems delay revenue recognition for large hardware replacements, creating backloaded adoption, forecasting uncertainty, and slower realization of total addressable market for new hardware cycles.
Tariff-Related Cost RiskOngoing tariff exposure is a structural margin headwind that increases COGS unpredictability and compresses gross margins. If tariffs persist or escalate, profit planning and multi-quarter margin targets may be chronically pressured absent pricing or sourcing changes.
Omnicell News
OMCL FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was $26.84 and its highest was $55.00 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is $1.72B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Apr 28, 2026. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.331 by $0.219.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.47.
How many shares outstanding does Omnicell have?
Omnicell has 45,478,910 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $0.55 in its last earnings report, beating expectations of $0.331. Following the earnings report the stock price went up 20.941%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in OMCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.00 (69.80% Upside)
$65.00 (69.80% Upside)
Blogger Sentiment
Bullish
OMCL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Bullish
Bullish news 79%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.35%
12-Months-Change
Fundamentals
Return on Equity
1.64%
Trailing 12-Months
Asset Growth
-6.85%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., founded in 1992 and headquartered in Mountain View, California (initially operating as Omnicell Technologies, Inc. until its name change in 2001), delivers advanced medication management technologies and patient adherence solutions. The company serves healthcare systems and pharmacies both domestically within the United States and globally. Its extensive portfolio of offerings includes: Clinical Workflow Automation: Omnicell provides automated solutions designed to streamline clinician tasks in patient care environments. This encompasses the XT Series automated dispensing units for medications and supplies across nursing units, clinical areas, and surgical suites. They also offer interface software to ensure smooth integration between their products and a healthcare facility's existing information systems, alongside robotic systems for automated storage and retrieval of packaged medications. Central Pharmacy Optimization: For the central pharmacy, Omnicell offers sophisticated automation, including automated storage and retrieval platforms like the XR2 Automated Central Pharmacy System. This segment also features robotic systems and workflow management tools for IV compounding, comprehensive inventory management software, and systems for controlled substance oversight. Single-Dose Packaging for Adherence: The company develops automated technologies for filling and labeling patient-specific, single-dose medication blister packaging according to prescriptions. This includes both fully and semi-automated equipment for institutional pharmacies to ensure precise packaging, along with blister card packaging and supplies aimed at improving medication adherence, particularly in non-acute care settings. Digital Patient Engagement: Omnicell further provides EnlivenHealth Patient Engagement, a web-based platform offering various tools to interact with patients.
OMCL Company Deck
OMCL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: robust top-line growth (+15% YoY), outsized improvement in profitability (non-GAAP EBITDA and EPS nearly doubling year-over-year), improved free cash flow, and constructive commercial traction following the Titan XT and OmniSphere launches. Management raised FY profitability guidance while maintaining revenue and bookings targets. Key risks discussed include near-term pacing of Titan XT adoption due to long capital cycles, a $12M tariff headwind, a lower cash balance after debt repayment and buybacks, and some potential quarter-to-quarter margin/revenue variability as expenses are phased throughout the year. On balance, positive execution, raised guidance, and a strong pipeline outweigh the timing and macro/cyclical headwinds.View all OMCL earnings summariesOMCL Stock 12 Month Forecast
Average Price Target
$65.00
▲(69.80% Upside)
Technical Analysis
Ownership Overview
3.00% Insiders
30.61% Mutual Funds
16.78% Other Institutional Investors
16.08% Public Companies and
Individual Investors